Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532006 | 1.00 | MRGPRX4 (0.42) | MRGPRX4SSTR4SPHK2RORCNOS3 | |
| SCHEMBL5523005 | 0.86 | SPHK2 (0.49) | SPHK2NOS3NOS1ACVR1MAPT | |
| SCHEMBL5523009 | 0.86 | SPHK2 (0.49) | SPHK2NOS3NOS1ACVR1MAPT | |
| SCHEMBL5520800 | 0.85 | S1PR1 (0.45) | SPHK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL5520796 | 0.85 | S1PR1 (0.45) | SPHK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL5524117 | 0.84 | MRGPRX4 (0.45) | MRGPRX4SSTR4NOS3NOS1HTR6 | |
| SCHEMBL5514929 | 0.82 | ACVR1 (0.40) | SPHK2ACVR1CCNE2CDK4CCND1 | |
| SCHEMBL5514924 | 0.82 | ACVR1 (0.40) | SPHK2ACVR1CCNE2CDK4CCND1 | |
| SCHEMBL5040525 | 0.82 | SPHK2 (0.53) | SPHK2NOS3NOS1MAPTTSHR | |
| SCHEMBL5035995 | 0.82 | SPHK2 (0.53) | SPHK2NOS3NOS1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166589-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | disclosed |
| CN-1289087-C | Quinoline derivatives as neuropeptide y antagonists | HOFFMANN LA ROCHE (CH) | 2006-12-13 | — | — | CN | disclosed |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | KLUG MICHAEL G | 2006-07-06 | — | — | US | disclosed |
| US-7064134-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | KLUG MICHAEL G | 2006-03-23 | — | — | US | disclosed |
| US-7012073-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| CN-1607951-A | Quinoline derivatives as neuropeptide y antagonists | HOFFMANN LA ROCHE (CH) | 2005-04-20 | — | — | CN | disclosed |
| US-20040259858-A1 | Quinoline derivatives | KLUG MICHAEL G (US) | 2004-12-23 | — | — | US | disclosed |
| US-6787558-B2 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS, FOR TREATING ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS AND OBESITY | HOFFMANN-LA ROCHE INC. | 2004-09-07 | — | — | US | disclosed |
| US-20030158179-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158179-A1 | Quinoline derivatives | RAB1A, GLS, REN | MRGPRX4 868/4885SSTR4 2897/4885SPHK2 2908/4885 |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | NPY1R, NPY2R, NPY4R | MRGPRX4 75/4885SSTR4 16/4885SPHK2 1818/4885 |
| US-20040259858-A1 | Quinoline derivatives | RAB1A, GLS, REN | MRGPRX4 868/4885SSTR4 2897/4885SPHK2 2908/4885 |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | NPY1R, NPY2R, NPY4R | MRGPRX4 81/4885SSTR4 15/4885SPHK2 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.